Latest Breaking News On - Adult leukemia program - Page 2 : comparemela.com

Researchers discover new target for potential leukemia therapy

Researchers discover new target for potential leukemia therapy
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Qingyu luoDana farber cancer instituteAdult leukemia program at dana farberAndrew laneAdult leukemia programCancer genome atlas data

Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Johno mascarenhasDynamic international prognostic scoring systemAdult leukemia programTisch cancer instituteMyeloproliferative disorders programIcahn school of medicine at mount sinaiIcahn schoolMount sinaiBlood cancersMyeloid disordersMyeloproliferative disordersMyelofibrosis symptom assessment formAdv hematolJak inhibitor naive myelofibrosisXport mf 044Xport mf 034

Pelabresib Plus Ruxolitinib Improves Spleen Volume Reduction in JAK Inhibitor-Naive Myelofibrosis

Treatment with the combination of pelabresib and ruxolitinib led to a statistically significant and clinically meaningful improvement in spleen volume reduction vs placebo plus ruxolitinib in patients with JAK inhibitor-naive myelofibrosis, meeting the primary end point of the phase 3 MANIFEST-2 trial.

New yorkUnited statesJohn mascarenhasRubena mesaTisch cancer institute at mount sinaiEuropean medicines agencyDynamic international prognostic scoring systemAtrium health levine cancer centerAdult leukemia programTisch cancer instituteMount sinaiManifest 2 trial

Ajax Therapeutics Appoints Dr David Steensma as Chief Medical Officer

NEW YORK (BUSINESS WIRE) Aug 23, 2023

United statesKathryn morrisDavid steensmaRoss levineMartin vogelbaumLaurence joseph dineenEdwardp evansDavidp steensmaHarvard medical schoolTranslational researchDivision of hematological malignanciesNovartis institutes for biomedical researchDana farber cancer instituteDivision of hematologyDepartment of medicineInstitute physician

MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21,

EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, June 14, 2023 MorphoS.

United statesNew yorkTim demuthJean paul kressJulia neugebauerGabriela hobbsJohn mascarenhasEamonn nolanThomas biegiDistribution servicesTisch cancer institute at mount sinaiConstellation pharmaceuticals incProfessor of medicine at harvard medical schoolAdult leukemia programExchange commissionLeukemia service at massachusetts